Back to top

Maxim Group Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)

Maxim Group analyst Naz Rahman reiterated a Buy rating on Assertio Therapeutics (ASRT – Research Report) today and set a price target of $3.00. The...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Assertio Holdings, Inc. (ASRT)